RoosterBio, Inc. has announced a new collaboration with Thermo Fisher Scientific to accelerate the availability of new, potentially life-saving cell and exosome therapies that have the potential to revolutionise the treatment of degenerative disease.

Uniting RoosterBio's extensive portfolio of hMSC-based products and processes with Thermo Fisher's advanced therapy GMP contract manufacturing capabilities, customers can access a new comprehensive solution for the development and manufacturing of hMSC and exosome therapeutics.

Specifically, biopharmaceutical companies will utilise RoosterBio's expertise in hMSC and exosome products, processes, and analytics along with Thermo Fisher's leading GMP manufacturing capabilities to accelerate their timelines for production of clinical trial materials. Manufacturing services provided by Thermo Fisher will include upstream expansion of hMSCs, downstream purification of MSCs and MSCderived exosomes, and drug product manufacturing.

Tim Kelly, Chief Executive Officer of RoosterBio said, “Thermo Fisher has an exceptional track record of success in the manufacture of clinical and commercial cell and gene therapies and a well-established global network to meet the needs of our customers. Biopharmaceutical companies striving to develop engineered cell and exosome therapies require proven, flexible technologies paired with reliable and scalable manufacturing capabilities. Through this collaboration, we will deliver that comprehensive solution to our customers, and I am delighted to work with Thermo Fisher to translate our MSC and exosome technologies into advanced therapy products for patients around the world.”

Ben Castro, Vice President and General Manager, Large Molecule, Pharma Services, Thermo Fisher commented, “Our collaboration with RoosterBio reflects our shared commitment to helping life-changing therapies reach patients in need, in the safest, fastest and most effective way possible. We're excited to work with the team to expand our Contract Development Manufacturing Organisation (CDMO) services and support our biotechnology partners through the research and optimisation, process development and manufacturing of critical treatments.”

Consistent with global best practices, RoosterBio prioritises the safety and efficacy of its products through robust bioethical standards, including hMSCs being sourced under stringent guidelines, manufactured using highly standardised processes, and supported by first-in-class characterisation.